세계의 항독소 시장 - 규모, 점유율, 동향 분석 보고서 : 종별, 유형별, 작용기전별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Anti-venom Market Size & Trends

The global anti-venom market size was estimated at USD 1.18 billion in 2023 and is expected to grow at a CAGR of 8.11% from 2024 to 2030. This growth is attributed to the rising prevalence of venom bites/stings, increasing awareness of anti-venom treatments, growing research initiatives to develop effective treatments, and growing government initiatives to spread. According to the World Health Organization (WHO), approximately 5.4 million people get bitten by snakes each year. Moreover, around 81 410 to 137 880 mortalities occur globally each year as a result of snake bites.

Similarly, several venomous species, such as spiders, scorpions, and others, also significantly contribute to the increasing demand for anti-venom treatments. Bites from these venomous species often lead to various serious conditions and acute medical emergencies such as severe paralysis, which may prevent breathing, lead to bleeding disorders, and may even cause irreversible kidney failure. The increasing awareness about these effects of venom bites and the need for their treatment are expected to fuel the market growth over the forecast period. The countries and regions with weaker health systems and resources experience an increased burden of these conditions caused by venom bites, highlighting the importance of these treatments.

Various research institutes, universities, and healthcare companies are taking initiatives to enhance their R&D on anti-venom for the development of advanced solutions with better results and outcomes. For instance, in October 2022, Monash University Malaysia and Agilent Technologies Inc. signed a MoU for building an integrated biology center in Malaysia. This center is anticipated to help the institutions improve their scientific knowledge to develop better anti-venom & other applied biology research. Similarly, in March 2024, the Institute for Primate Research Kenya announced that it is ready to introduce the first-ever anti-venom produced in any African country. Such research initiatives taken by various institutions are expected to lead to the development of advanced treatments and drive market growth.

Similarly, several governments globally are trying to increase awareness about venomous species and the effects of their bites, which is further anticipated to contribute to market growth. For instance, in MAR 2024, the Union Health Ministry of the Government of India (GOI) launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) in India. A snakebite helpline no was also launched at the event to ensure better access to medical care for the individuals or communities affected by snakebites in five different states of the country. Such increasing government initiatives to increase medical care access for venom bite victims are anticipated to fuel the anti-venom market growth over the forecast period.

Global Anti-venom Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global anti-venom market report based on species, type, mode of action, end-use, and region:

• Species Outlook (Revenue, USD Million, 2018 - 2030)
• Snake
• Common Cobra
• Common Krait
• Russell Viper
• Others
• Scorpion
• Spider
• Other Species
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Polyvalent
• Monovalent
• Mode Of Action Outlook (Revenue, USD Million, 2018 - 2030)
• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Species
  • 1.2.2. Type
  • 1.2.3. Mode of Action
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Species outlook
  • 2.2.2. Type outlook
  • 2.2.3. Mode of Action outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Anti-Venom Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidents of venom-bites
    • 3.2.1.2. Increasing R&D initiatives
    • 3.2.1.3. Increasing awareness about importance of anti-venom
    • 3.2.1.4. Rising government initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited access to the treatments
• 3.3. Anti-Venom Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
  • 3.3.2. PESTEL Analysis

Chapter 4. Anti-Venom Market: Species Estimates & Trend Analysis

• 4.1. Species Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Anti-Venom Market by Species Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Snakes
    • 4.4.1.1. Snakes market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Common cobra
    • 4.4.1.2.1. Common cobra market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Common krait
    • 4.4.1.3.1. Common krait market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Rusell viper
    • 4.4.1.4.1. Rusell viper market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Others
    • 4.4.1.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Scorpion
    • 4.4.2.1. Scorpion market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Spider
    • 4.4.3.1. Spider market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Other species
    • 4.4.4.1. Other species market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anti-Venom Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Anti-Venom Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Polyvalent
    • 5.4.1.1. Polyvalent market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Monovalent
    • 5.4.2.1. Monovalent market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

• 6.1. Mode of action Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Anti-Venom Market by Mode of Action Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Cytotoxic
    • 6.4.1.1. Cytotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Neurotoxic
    • 6.4.2.1. Neurotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Haemotoxic
    • 6.4.3.1. Haemotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Cardiotoxic
    • 6.4.4.1. Cardiotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Myotoxic
    • 6.4.5.1. Myotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anti-Venom Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Anti-Venom Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospitals
    • 7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Clinics
    • 7.4.2.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Ambulatory surgical centers
    • 7.4.3.1. Ambulatory surgical centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Others
    • 7.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Anti-Venom Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ Reimbursement
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ Reimbursement
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ Reimbursement
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ Reimbursement
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Denmark
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ Reimbursement
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.9. Norway
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ Reimbursement
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ Reimbursement
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ Reimbursement
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ Reimbursement
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ Reimbursement
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/ Reimbursement
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ Reimbursement
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ Reimbursement
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ Reimbursement
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ Reimbursement
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Bharat Serums and Vaccines Limited (BSV)
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Others benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Boehringer Ingelheim International GmbH
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Others benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Boston Scientific Corporation
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Others benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. CSL Limited
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Others benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Haffkine Bio-Pharmaceutical Corporation Limited
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Others benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Incepta Pharmaceuticals Limited
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Others benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Merck & Co., Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Others benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Pfizer, Inc.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Others benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. MicroPharm Limited
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Others benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Rare Disease Therapeutics Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Others benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. South African Vaccine Producers (Pty) Ltd.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Others benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Medtoxin Venom Laboratories
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Others benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Instittue of Immunology
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Others benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Alomone Labs, Ltd.
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Others benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. Sigma Aldrich
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Others benchmarking
    • 9.3.18.4. Strategic initiatives